$2.59 Billion is the total value of Rock Springs Capital Management LP's 131 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ONCE | SPARK THERAPEUTICS INC | $61,211,000 | +191.0% | 537,500 | 0.0% | 2.36% | +137.7% | |
| HCA | HCA HEALTHCARE INC | $59,323,000 | +4.8% | 455,000 | 0.0% | 2.29% | -14.4% | |
| PCRX | PACIRA PHARMACEUTICALS INC | $47,575,000 | -11.5% | 1,250,000 | 0.0% | 1.83% | -27.7% | |
| TFX | TELEFLEX INC | $39,281,000 | +16.9% | 130,000 | 0.0% | 1.51% | -4.5% | |
| VRTX | VERTEX PHARMACEUTICALS INC | $37,342,000 | +11.0% | 203,000 | 0.0% | 1.44% | -9.3% | |
| SYK | STRYKER CORP | $35,356,000 | +26.0% | 179,000 | 0.0% | 1.36% | +2.9% | |
| EW | EDWARDS LIFESCIENCES CORP | $35,109,000 | +24.9% | 183,500 | 0.0% | 1.35% | +2.0% | |
| PEN | PENUMBRA INC | $33,077,000 | +20.3% | 225,000 | 0.0% | 1.28% | -1.8% | |
| ALXN | ALEXION PHARMACEUTICALS INC | $32,781,000 | +38.8% | 242,500 | 0.0% | 1.26% | +13.5% | |
| ALGN | ALIGN TECHNOLOGY INC | $29,855,000 | +35.8% | 105,000 | 0.0% | 1.15% | +10.9% | |
| BGNE | BEIGENE LTDsponsored adr | $28,354,000 | -5.9% | 214,800 | 0.0% | 1.09% | -23.1% | |
| INSM | INSMED INC | $24,710,000 | +121.6% | 850,000 | 0.0% | 0.95% | +81.2% | |
| BAX | BAXTER INTL INC | $24,450,000 | +23.5% | 300,700 | 0.0% | 0.94% | +1.0% | |
| CELG | CELGENE CORP | $17,467,000 | +47.2% | 185,150 | 0.0% | 0.67% | +20.2% | |
| FGEN | FIBROGEN INC | $16,631,000 | +17.4% | 306,000 | 0.0% | 0.64% | -4.0% | |
| ALLK | ALLAKOS INC | $16,362,000 | -22.5% | 404,000 | 0.0% | 0.63% | -36.7% | |
| XENT | INTERSECT ENT INC | $14,950,000 | +14.1% | 465,000 | 0.0% | 0.58% | -6.9% | |
| A | AGILENT TECHNOLOGIES INC | $14,693,000 | +19.1% | 182,800 | 0.0% | 0.57% | -2.7% | |
| OBSV | OBSEVA SA | $14,325,000 | +1.0% | 1,120,000 | 0.0% | 0.55% | -17.5% | |
| FOLD | AMICUS THERAPEUTICS INC | $13,600,000 | +42.0% | 1,000,000 | 0.0% | 0.52% | +15.9% | |
| BHVN | BIOHAVEN PHARMACTL HLDG CO L | $13,382,000 | +39.2% | 260,000 | 0.0% | 0.52% | +13.7% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $12,968,000 | +28.9% | 245,000 | 0.0% | 0.50% | +5.3% | |
| ZGNX | ZOGENIX INC | $12,927,000 | +50.9% | 235,000 | 0.0% | 0.50% | +23.3% | |
| AXGN | AXOGEN INC | $12,720,000 | +3.1% | 603,970 | 0.0% | 0.49% | -15.8% | |
| TBPH | THERAVANCE BIOPHARMA INC | $12,469,000 | -11.4% | 550,000 | 0.0% | 0.48% | -27.6% | |
| RTIX | RTI SURGICAL HOLDINGS INC | $11,720,000 | +62.4% | 1,950,000 | 0.0% | 0.45% | +32.6% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $10,794,000 | +11.7% | 4,200,000 | 0.0% | 0.42% | -8.8% | |
| TBIO | TRANSLATE BIO INC | $10,284,000 | +35.9% | 1,009,179 | 0.0% | 0.40% | +10.9% | |
| FRPT | FRESHPET INC | $9,938,000 | +31.5% | 235,000 | 0.0% | 0.38% | +7.3% | |
| ODT | ODONATE THERAPEUTICS INC | $9,839,000 | +57.0% | 445,000 | 0.0% | 0.38% | +28.0% | |
| AXNX | AXONICS MODULATION TECH INC | $9,580,000 | +58.5% | 400,000 | 0.0% | 0.37% | +29.5% | |
| NVCR | NOVOCURE LTD | $9,393,000 | +43.9% | 195,000 | 0.0% | 0.36% | +17.5% | |
| CHRS | COHERUS BIOSCIENCES INC | $9,139,000 | +50.7% | 670,000 | 0.0% | 0.35% | +23.1% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $8,861,000 | -12.9% | 450,000 | 0.0% | 0.34% | -28.8% | |
| MYOV | MYOVANT SCIENCES LTD | $8,295,000 | +45.5% | 347,500 | 0.0% | 0.32% | +19.0% | |
| CMTA | CLEMENTIA PHARMACEUTICALS IN | $7,178,000 | +122.0% | 275,000 | 0.0% | 0.28% | +81.0% | |
| BLUE | BLUEBIRD BIO INC | $7,080,000 | +58.6% | 45,000 | 0.0% | 0.27% | +29.4% | |
| FPRX | FIVE PRIME THERAPEUTICS INC | $6,767,000 | +44.1% | 505,000 | 0.0% | 0.26% | +17.6% | |
| SPRO | SPERO THERAPEUTICS INC | $6,725,000 | +108.3% | 525,000 | 0.0% | 0.26% | +70.4% | |
| CO | GLOBAL CORD BLOOD CORPORATIO | $6,494,000 | +8.9% | 925,000 | 0.0% | 0.25% | -11.3% | |
| CLVS | CLOVIS ONCOLOGY INC | $6,354,000 | +38.2% | 256,000 | 0.0% | 0.24% | +12.9% | |
| INSMED INCnote 1.750% 1/1 | $6,082,000 | +41.6% | 6,000,000 | 0.0% | 0.23% | +15.3% | ||
| RYTM | RHYTHM PHARMACEUTICALS INC | $5,934,000 | +2.0% | 216,500 | 0.0% | 0.23% | -16.7% | |
| MNTA | MOMENTA PHARMACEUTICALS INC | $5,812,000 | +31.6% | 400,000 | 0.0% | 0.22% | +7.7% | |
| BCRX | BIOCRYST PHARMACEUTICALS | $5,698,000 | +0.9% | 700,000 | 0.0% | 0.22% | -17.6% | |
| ARDX | ARDELYX INC | $5,600,000 | +56.4% | 2,000,000 | 0.0% | 0.22% | +27.8% | |
| ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $4,798,000 | +19.9% | 5,000,000 | 0.0% | 0.18% | -2.1% | ||
| CGEN | COMPUGEN LTDord | $4,554,000 | +90.8% | 1,100,000 | 0.0% | 0.18% | +55.8% | |
| MEDICINES COnote 2.750% 7/1 | $4,231,000 | +11.5% | 5,000,000 | 0.0% | 0.16% | -8.9% | ||
| NABRIVA THERAPEUTICS PLC | $3,904,000 | +67.1% | 1,600,000 | 0.0% | 0.15% | +37.3% | ||
| CORV | CORREVIO PHARMA CORP | $3,792,000 | +26.9% | 1,200,000 | 0.0% | 0.15% | +3.5% | |
| MEDICINES COnote 2.500% 1/1 | $3,013,000 | +16.4% | 3,000,000 | 0.0% | 0.12% | -4.9% | ||
| DVAX | DYNAVAX TECHNOLOGIES CORP | $2,778,000 | -20.1% | 380,000 | 0.0% | 0.11% | -34.8% | |
| TORC | RESTORBIO INC | $2,728,000 | -20.9% | 400,000 | 0.0% | 0.10% | -35.6% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $2,412,000 | +4.5% | 450,000 | 0.0% | 0.09% | -14.7% | |
| ARVN | ARVINAS INC | $2,214,000 | +14.8% | 150,000 | 0.0% | 0.08% | -6.6% | |
| NVAX | NOVAVAX INC | $1,790,000 | -70.1% | 3,250,000 | 0.0% | 0.07% | -75.5% | |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $1,783,000 | -31.8% | 277,236 | 0.0% | 0.07% | -43.9% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $1,608,000 | +9.5% | 400,000 | 0.0% | 0.06% | -10.1% | |
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,457,000 | -5.8% | 1,500,000 | 0.0% | 0.06% | -23.3% | ||
| NEUROCRINE BIOSCIENCES INCnote 2.250% 5/1 | $1,354,000 | +13.2% | 1,000,000 | 0.0% | 0.05% | -7.1% | ||
| RADIUS HEALTH INCnote 3.000% 9/0 | $1,249,000 | +8.0% | 1,500,000 | 0.0% | 0.05% | -12.7% | ||
| PACIRA PHARMACEUTICALS INCnote 2.375% 4/0 | $987,000 | -0.7% | 1,000,000 | 0.0% | 0.04% | -19.1% | ||
| DERMIRA INCnote 3.000% 5/1 | $888,000 | +14.6% | 1,000,000 | 0.0% | 0.03% | -8.1% | ||
| PTI | PROTEOSTASIS THERAPEUTICS IN | $504,000 | -61.1% | 400,000 | 0.0% | 0.02% | -68.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.